GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension
Geneva, Switzerland, September 21, 2021 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a first patient having completed its ProTEct-MS study at Karolinska Institutet’s Academic Specialist Center (ASC) in […]